---
title: "EyePoint shareholders approve 4.9 million-share increase to 2023 incentive plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290425050.md"
description: "EyePoint Pharmaceuticals shareholders approved an amendment to the 2023 long-term incentive plan, increasing authorized share issuance by 4.9 million shares. Additionally, they ratified Deloitte & Touche as the independent registered public accounting firm for fiscal 2026 during the annual meeting held on June 18, 2026."
datetime: "2026-06-22T11:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290425050.md)
  - [en](https://longbridge.com/en/news/290425050.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290425050.md)
generator: "portal-rs"
---

# EyePoint shareholders approve 4.9 million-share increase to 2023 incentive plan

-   EyePoint held its annual shareholder meeting on June 18, 2026. \* Shareholders adopted an amendment to the 2023 long-term incentive plan, increasing authorized share issuance by 4,900,000 shares. \* Shareholders ratified Deloitte & Touche as independent registered public accounting firm for fiscal 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-276688), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)

## Related News & Research

- [EyePoint director Karen Zaderej reports purchase of 10,600 shares worth $52,258](https://longbridge.com/en/news/296265357.md)
- [EyePoint says Phase 3 LUGANO trial of DURAVYU in wet AMD misses primary endpoint](https://longbridge.com/en/news/296094908.md)
- [EyePoint stock craters 71% after drug trial failure. It may be an overreaction.](https://longbridge.com/en/news/296132806.md)
- [These Analysts Slash Their Forecasts On EyePoint](https://longbridge.com/en/news/296252754.md)
- [13:03 ETEYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals](https://longbridge.com/en/news/296520819.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**